Focus: Marea Therapeutics is a pre-revenue biotech focused on cardiometabolic disease treatments, headquartered in South San Francisco with a public listing status. The company operates as a small, focused pipeline player in metabolic disease with early-stage clinical programs.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Marea Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Marea Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Marea Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Marea Therapeutics to Present Data from Phase 1 Study of MAR002 for the Treatment of Acromegaly at ENDO 2026 - Business Wire
Marea Therapeutics to Present Data from Phase 1 Study of MAR002 for the Treatment of Acromegaly at ENDO 2026 Business Wire
Fulcrum taps ex-Graphite Bio CEO with Oxbryta experience for board - Stock Titan
Fulcrum taps ex-Graphite Bio CEO with Oxbryta experience for board Stock Titan
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight - Nasdaq
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight Nasdaq
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo